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[73.2 (15.4)] and did not improve over time. 76% had behavioural
disorders already evident during hospitalization. Upon discharge, 62%
required adapted and/or specialized schooling. After an average
follow-up of 8 and a half years, only 6 patients still followed an
ordinary curriculum and 8 were not attending school anymore. Four
girls were victims, and among 36 boys, all were perpetrators, but 3
had been victims previously. The offenses were mainly cases of
violence (56%), but also entailed thefts, trafﬁc offences, sexual
assaults, drug use and vandalism.
Discussion Children with ABI who suffer or commit offenses are
mainly boys, from very low socioeconomic background, with pre-
injury academic and social difﬁculties, who sustained severe TBI.
They suffer very severe and disabling cognitive deﬁcits and
behavioral disorders. Multidisciplinary care and follow-up of those
children more at risk is essential in the long-term.
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Introduction Craniopharyngioma is a rare, benign central ner-
vous system tumor, which may be source of multiple complica-
tions, from endocrinology to vision, neurology and neurocognitive
fonctions. This morbidity can lead to participation restrictions, as
described in the International Clasiﬁcation of Functioning. Primary
objective of this studywas tomeasure participation in a population
of children and young adults having been affected by a childhood
carniopharyngioma, using the LIFE-H questionnaire (Assessment
of Life Habits), valid as a participationmeasure in various pediatric
disabilities. We also examined potential links between the tumor
characteristics, the complications and the participation.
Patients and methods Descriptive, multicenter study, including
all patients having presented a childhood craniopharyngioma
(before 18), followed in Lyon region between 2007 and 2013. Main
criteria was the LIFE-H results, completed by the patient or the
carer.
Results On 21 patients included in the study, 14 have completed
the questionnaire, with a mean answer delay of 6.7 years after the
diagnosis (SD: 3.9 years). Mean total LIFE-H score was 8.4 (SD:
1.03) for a normal score estimated at 10 in general population. The
lowest scores affected nutrition, community life and recreation
dimensions. All patients had a endocrinological deﬁcit, 19% an
hypothalamic syndrome, 52% an impaired fullﬁlness feeling, 76%
visual impairment, 14% a neurologic impairment, 91% a neuro-
cognitive impairment. 57% of all patients could keep on attending a
normal school, 43% had to enter a speciﬁc school. In patients in
speciﬁc school, LIFE-H results were signiﬁcantly lower in nutrition,
communication, housing and recreation dimensions.
Conclusion Patients with childhood craniopharyngioma have
their participation affected, mainly in the social dimensions. We
could enhance it with systematic diagnosis of those participation
impairements, with the goal of a suitable multidisciplinary
management.
Keywords Childhood cranioharyngioma; Morbidity; Participa-
tion; LIFE-H
Disclosure of interest The authors have not supplied their
declaration of conﬂict of interest.
http://dx.doi.org/10.1016/j.rehab.2015.07.330
CO51-008-e
Promoting the use of Motor Function
Measure (MFM) as outcome measure
in patients with Duchenne Muscular
Dystrophy (DMD) treated by
corticosteroids
A. Schreiber-Bontemps a,*, S. Brochard (Dr)a,
S. Fontaine-Carbonnel (Dr)b, S. Chabrier (Dr)c,
V. Gautheron (Dr)c, S. Peudenier (Dr)a, P. Rippert a,
H. Rauscent (Dr)d, F. Rivier (Dr)e, J. Andoni
Urtizberea (Dr)f, M. Fournier-Mehouas (Dr)g,
J.Y. Mahe´ (Dr)h, V. Tiffreau (Dr)i, E. Lagrue (Dr)j,
D. Hamroun k, I. Poirot (Dr)b, S. Ragot-Mandry (Dr)l,
S. Sacconi (Dr)g, B. Puy Haubert e, C. Faﬁn g,
C. Vuillerot (Dr)b
a CHRU de Brest, Brest, France
b CHU de Lyon
c CHU de St-E´tienne
d CHU de Rennes
e CHU de Montpellier
f Hoˆpital Marin de Hendaye (APHP)
g CHU de Nice
h CRRF de Pen Bron
i CHRU de Lille
j CHRU de Tours
k CHRU de Montpellier
l CHU de Nancy
*Corresponding author.
E-mail address: schreiberaudrey@yahoo.fr (A. Schreiber-ontemps)
Objectives Assessing muscle function is a key step in measuring
changes and evaluating the outcomes of therapeutic interventions
in Duchenne Muscular Dystrophy (DMD). Regarding the large use
of corticosteroids (CS) in this population to delay the loss of
function, our goal was to monitor the evolution of motor function
in patients with DMD treated by corticosteroids (CS) and to study
the responsiveness of Motor Function Measure (MFM) in this
population in order to provide an estimation of the number of
subject needed for a clinical trial.
Method A total of 76 patients with DMD, aged 5.9 to 11.8 years,
with at least 6months of follow-up and 2MFMwere enrolled, 30 in
the CS treated group (8  1.62 y) and 46 in the untreated group
(7.91  1.50 y).
Results The relationship between MFM scores and age was
studied in CS treated patients and untreated patients. The
evolution of these scores was compared between groups, on a
6-, 12- and 24-month period by calculating slopes of change and
standardized response mean. At 6, 12 and 24 months, signiﬁcant
differences in the mean score change were found, for all MFM
scores, between CS treated patients and untreated patients. For D1
subscore speciﬁcally, at 6 months, the increase is signiﬁcant in the
treated group (11.3  14%/y; SRM 0.8) while a decrease is observed
in the untreated group (–17.8  17.7%/y; SRM 1). At 12 and 24
months, D1 subscore stabilized for treated patients but declined
signiﬁcantly for untreated boys (–15.5  15.1%/y; SRM 1 at 12 mo
and–18.8  7.1%/y; SRM 2.6 at 24 mo). 21 patients lost the ability to
walk during the study: 6 in the CS treated group (25% at 24 months,
mean age: 10.74  1.28 y) and 15 in the untreated group (64.71% at
24 months, mean age: 9.20  1.78 y).
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